To investigate the role of AGO2 in the development of pancreatic cancer in vivo, we employed the GEMM of pancreatic cancer initiated by a conditionally activated allele of KRAS4, KRASLSL−G12D/+ (KRASG12D, Fig. 1a). This evidence concerns the gene AGO2 and pancreatic neoplasm.